Study drug for infection-related lung failure in adults
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You developed ARDS after an infection within the last 7 days, based on chest imaging (usually X-ray/scan) showing problems in both lungs
- Your breathing problem started recently—moderate to severe ARDS symptoms for 48 hours or less—often needing breathing support like a ventilator, CPAP/BiPAP, or high-flow oxygen
- You can sign consent yourself or have a legally allowed person sign for you
- If you can become pregnant or have a partner who could, you must use two reliable birth-control methods (and you cannot donate sperm/eggs during the study and for 3 months after)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
This trial tests a new medicine called MRG-001 for people with severe lung injury (ARDS) who need breathing support. It aims to help the lungs heal and reduce inflammation.
This trial tests a new drug (R-3750) given by mouth through a feeding tube for patients with severe lung injury (ARDS) that hasn't improved after one to four weeks of intensive care. The goal is to see if the drug helps patients recover better.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
This trial tests whether erythropoietin (EPO), a medicine that affects red blood cell production, can help clear extra fluid from the lungs in people with acute respiratory distress syndrome (ARDS). If it works, it could improve breathing and reduce lung fluid buildup during critical illness.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.